Additional file 1 of Acazicolcept (ALPN-101), a dual ICOS/CD28 antagonist, demonstrates efficacy in systemic sclerosis preclinical mouse models

Orvain, Cindy; Cauvet, Anne; Prudent, Alexis; Guignabert, Christophe; Thuillet, Raphaël; Ottaviani, Mina; Tu, Ly; Duhalde, Fanny; Nicco, Carole; Batteux, Frédéric; Avouac, Jérôme; Wang, NingXin; Seaberg, Michelle A.; Dillon, Stacey R.; Allanore, Yannick

doi:10.6084/m9.figshare.17913175.v1

13075_2021_2709_MOESM1_ESM.pptx (41.11 kB)

Additional file 1 of Acazicolcept (ALPN-101), a dual ICOS/CD28 antagonist, demonstrates efficacy in systemic sclerosis preclinical mouse models

presentation

posted on 2022-01-06, 04:29 authored by Cindy Orvain, Anne Cauvet, Alexis Prudent, Christophe Guignabert, Raphaël Thuillet, Mina Ottaviani, Ly Tu, Fanny Duhalde, Carole Nicco, Frédéric Batteux, Jérôme Avouac, NingXin Wang, Michelle A. Seaberg, Stacey R. Dillon, Yannick Allanore

Additional file 1: Supplementary Table 1. Clinical characteristics of the SSc cohort. ICOS serum levels were analysed on a cohort of 161 patients affected by SSc.

Funding

Alpine Immune Sciences

History

Usage metrics

Keywords

Systemic sclerosis Dermal fibrosis Pulmonary fibrosis Pulmonary hypertension Costimulation blockade ICOS CD28

Licence

CC BY + CC0

Exports

RefWorks

BibTeX

Ref. manager

Endnote

DataCite

NLM

DC

Additional file 1 of Acazicolcept (ALPN-101), a dual ICOS/CD28 antagonist, demonstrates efficacy in systemic sclerosis preclinical mouse models

Funding

Alpine Immune Sciences

History

Usage metrics

Categories

Keywords

Licence

Exports